Repligen is developing a pipeline of innovative products and therapies with the potential to make a significant impact in the lives of patients suffering from diseases with limited treatment options. The company’s diverse pipeline includes the following development programs:
SecreFlo(TM), synthetic human secretin, positive Phase 3 study completed to improve magnetic resonance imaging of the pancreas.
SecreFlo(TM), synthetic human secretin, investigator led pilot studies to improve pancreatic cancer detection.
RG3039, promoters of SMN2 gene expression, entering Phase 1 for spinal muscual atrophy.
RG2833, HDAC (Class 1) inhibitors, in preclinical development for Friedreich’s ataxia.
Call Banksia on 1300 769 944, +617 3902 3000, email or complete the below form.